IFNA pathway drives the more aggressive phenotype of KRAS G12D -mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation

作者
Koetsu Inoue,Daniel Hendrik Schanne,Aya Matsui,Pin‐Ji Lei,Sebastian Klein,Shuichi Aoki,Hajime Taniguchi,Hiroto Kikuchi,Chen Jiang,Zelong Liu,Shengdar Q. Tsai,Tyge CE Schmidt,Masaaki Iwasaki,Glenn Geidel,Alexander Hemdorff Koch,Peigen Huang,Dai Fukumura,Toshi Shioda,Lance L. Munn,Carlos F. Fernandez-del Castillo
出处
期刊: [Cold Spring Harbor Laboratory]
标识
DOI:10.1101/2022.06.29.497540
摘要

Abstract Activating mutations of KRAS play critical roles in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC). Accumulating evidence indicates that distinct KRAS alleles associate with different prognoses, but the underlying mechanisms are not known. We established isogenic KRAS mutants ( KRAS G12D , KRAS G12V , and KRAS WT ) using a KRAS G12R patient-derived PDAC cell line by CRISPR/Cas9 knock-in. We used these isogenic cell lines, a collection of characterized human PDAC patient-derived cell lines, and murine PDAC models to study the role of these KRAS alleles in vitro and in vivo . We verified that the growth of KRAS G12D cells is more aggressive compared to KRAS G12V isogenic cells in vitro and in vivo using orthotopic mouse models. Signal transducer and activator of transcription (STAT) activation was the most significant difference between KRAS G12D and KRAS G12V isogenic PDACs. Furthermore, activation of interferon-alpha (IFNA)/IFNA receptor (IFNAR)1/STAT3 signaling in the cancer cells mediated the more aggressive phenotype of KRAS G12D PDACs. Conversely, inhibition of IFNAR1 in patient-derived PDAC cells suppressed tumor growth. Finally, IFNAR1 blockade was also effective in murine PDAC models and induced a significant increase in survival when combined with immune checkpoint blockade therapy. We conclude that the IFNA pathway and IFNAR1/STAT3 axis contribute to a more aggressive tumor progression in human KRAS G12D PDACs and that IFNAR1 inhibition is a potential therapeutic target for overcoming resistance to immunotherapy in PDAC. One Sentence Summary IFNA pathway drives the more aggressive phenotype of KRAS G12D -mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
外向夜春完成签到 ,获得积分10
2秒前
小艾同学发布了新的文献求助10
2秒前
Roux给Roux的求助进行了留言
3秒前
善良的采蓝的应助被土豪的城采纳,获得30
3秒前
hhh发布了新的文献求助10
5秒前
Davin_ji完成签到 ,获得积分10
5秒前
星辰大海的应助被wwwwwl采纳,获得10
6秒前
6秒前
7秒前
7秒前
8秒前
椰子鸡完成签到 ,获得积分10
8秒前
8秒前
8秒前
Charles完成签到,获得积分10
9秒前
9秒前
9秒前
fantasy的应助被隔岸采纳,获得10
9秒前
芽卉完成签到 ,获得积分10
10秒前
爆米花的应助被鼻毛好胜采纳,获得10
10秒前
乐乐的应助被111采纳,获得10
11秒前
WZJ发布了新的文献求助30
11秒前
chaoqi完成签到,获得积分10
12秒前
CipherSage的应助被Leonard采纳,获得10
12秒前
Danny完成签到,获得积分20
12秒前
13秒前
YANG完成签到,获得积分10
13秒前
哈哈哈发布了新的文献求助10
14秒前
颜玖笙发布了新的文献求助10
15秒前
hhh完成签到,获得积分20
16秒前
暴龙战士发布了新的文献求助10
16秒前
17秒前
郭啦啦啦啦完成签到 ,获得积分10
17秒前
陆地完成签到,获得积分10
19秒前
21秒前
酷波er的应助被开朗紫采纳,获得10
21秒前
鼻毛好胜发布了新的文献求助10
21秒前
泍泍完成签到 ,获得积分10
22秒前
波波子发布了新的文献求助20
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552